Analysts Adjust Ovid Therapeutics Price Targets H.C. Wainwright and BTIG have lowered their price targets for Ovid Therapeutics to $2 and $4, respectively, citing strategic shifts and paused developments. However, both firms maintain a Buy rating, emphasizing optimism in the company’s pipeline, particularly the OV329 program, as a potential growth driver.145